Cargando…
Skipping the co-expression problem: the new 2A "CHYSEL" technology
The rapid progress in the field of genomics is increasing our knowledge of multi-gene diseases. However, any realistic hope of gene therapy treatment for those diseases needs first to address the problem of co-ordinately co-expressing several transgenes. Currently, the use of internal ribosomal entr...
Autor principal: | de Felipe, Pablo |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC521497/ https://www.ncbi.nlm.nih.gov/pubmed/15363111 http://dx.doi.org/10.1186/1479-0556-2-13 |
Ejemplares similares
-
The Dilemma of Choice for Duchenne Patients Eligible for Exon 51 Skipping The European Experience
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2023) -
What Can We Learn From Clinical Trials of Exon Skipping for DMD?
por: Lu, Qi-long, et al.
Publicado: (2014) -
CRISPR-Cas9-mediated exon skipping as a cardioprotective strategy in Duchenne muscular dystrophy
por: Wilton-Clark, Harry, et al.
Publicado: (2023) -
New Targets and New Technologies in the Treatment of Parkinson’s Disease: A Narrative Review
por: Montemurro, Nicola, et al.
Publicado: (2022) -
Breakfast: To Skip or Not to Skip?
por: Zilberter, Tanya, et al.
Publicado: (2014)